Search
for
Sort by
Research 241–270 of 778
- The role of janus kinases in the treatment of autoimmune skin diseases
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- 211 Effect of 1α,25-dihydroxyvitamin D3 on mechanical properties of hairless mouse skin
- Keratin 6A promotes skin inflammation through JAK1-STAT3 activation in keratinocytes
- Forging the Future: 2018 Alopecia Areata Research Summit Summary Report
- The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- Innate type 2 immunity controls hair follicle commensalism by Demodex mites
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Kaempferol enhances hair growth by regulating JAK3/STAT6 and TGF-β/Smad signaling in human dermal papilla cells and a C57BL/6 mousemodel
- Updates From 2021 Virtual Dermatology Nurses' Association Convention
- Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
- Surgical Approaches for Repigmenting Vitiligo 2.0
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Molecular crosstalk between lncRNA H19, miR-29a, and JAK2/STAT3 signaling in alopecia areata: a preliminary study
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Alopecia Areata: An Updated Review for 2023
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Genetic Variants and Protective Immunity against SARS-CoV-2
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Androgenetic alopecia – Update 2022
- Update From Dermatology Nurses’ Association Convention 2025
- Proceedings of the Ninth World Congress for Hair Research (2015)
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial